Patent US2418643A successfully refreshed from Google Patents.
Patent US4195085A successfully refreshed from Google Patents.
US4195085A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions and methods for treating glaucoma by the topical administration of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy-2-phopanol hydrogen maleate
Assignee: Merck and Co Inc
•
Filing: 1978-08-29
•
Granted: 1980-03-25
•
Expires: 1998-08-29
Abstract
Abstract Antiglaucoma compositions containing t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate and method of treating elevated intraocular pressure.
Inventors
- 👤 Clement A. Stone
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 07:03
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/535; A61K9/00; A61K9/0012; A61K9/0048
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
28 words
A method for treating glaucoma and for lowering intraocular pressure which comprises topically applying to the glaucomatous eye an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.
Claim 2
Independent Claim
28 words
A method for treating glaucoma and for lowering intraocular pressure which comprises topically applying to the glaucomatous eye an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.
Claim 3
Dependent Claim
17 words
A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered in a water soluble polymeric insert.
Claim 4
Dependent Claim
11 words
A method according to claim 2 wherein the polymer is hydroxypropylcellulose.
Claim 5
Dependent Claim
24 words
A method according to claim 1 wherein the t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol is administered as a 0.01 to 5% solution of t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol in an ophthalmologically acceptable carrier.
Claim 6
Dependent Claim
27 words
An ophthalmic composition for the topical treatment of glaucoma comprising in solution an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazole-3-yloxy)-2-propanol hydrogen maleate and a liquid ophthlamic carrier.
Claim 7
Dependent Claim
27 words
An ophthalmic composition for the topical treatment of glaucoma comprising in solution an intraocular pressure lowering effective amount of t-butylamino-3-(4-morpholino-1,2,5-thiadiazole-3-yloxy)-2-propanol hydrogen maleate and a liquid ophthlamic carrier.
Claim 8
Dependent Claim
17 words
A composition according to claim 5 wherein the solution is from 0.01 to 5% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.
Claim 9
Dependent Claim
17 words
A composition according to claim 5 wherein the solution is from 0.5 to 2% t-butylamino-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)-2-propanol hydrogen maleate.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-03-25 | 1983-09-24 | 1984-03-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-03-25 | 1987-09-24 | 1988-03-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-03-25 | 1991-09-24 | 1992-03-25 | $7700.00 | Window Closed / Lapsed |